|
DAGLA expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.33066907387547E-16 |
| Normal-vs-Stage2 |
3.04730000122433E-08 |
| Normal-vs-Stage3 |
2.7787994127948E-11 |
| Normal-vs-Stage4 |
5.55119999967602E-08 |
| Stage1-vs-Stage2 |
4.881400E-01 |
| Stage1-vs-Stage3 |
9.870000E-01 |
| Stage1-vs-Stage4 |
6.248200E-01 |
| Stage2-vs-Stage3 |
5.469000E-01 |
| Stage2-vs-Stage4 |
3.495000E-01 |
| Stage3-vs-Stage4 |
6.781600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62458935193399E-12 |
| Normal-vs-AfricanAmerican |
5.574300E-04 |
| Normal-vs-Asian |
1.12480025293848E-10 |
| Caucasian-vs-AfricanAmerican |
3.405000E-01 |
| Caucasian-vs-Asian |
7.704400E-01 |
| AfricanAmerican-vs-Asian |
2.534600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.00940375449932E-11 |
| Normal-vs-Female |
1.11022302462516E-16 |
| Male-vs-Female |
5.087000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.7430501486615E-14 |
| Normal-vs-Age(41-60Yrs) |
4.10782519111308E-15 |
| Normal-vs-Age(61-80Yrs) |
1.0849998677287E-10 |
| Normal-vs-Age(81-100Yrs) |
3.962500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.600800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.970000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.940000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.090000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.860800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.109200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.923200E-01 |
| Classical-VS-Follicular |
4.353900E-04 |
| Classical-VS-Other |
3.168600E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
1.815390E-01 |
| Tall-VS-Other |
6.249800E-01 |
| Tall-VS-Normal |
5.58790000049214E-07 |
| Follicular-VS-Other |
8.679000E-01 |
| Follicular-VS-Normal |
4.08559999998115E-06 |
| Other-VS-Normal |
1.604250E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.98570065840431E-14 |
| Normal-vs-N1 |
5.39700000246057E-08 |
| N0-vs-N1 |
9.585000E-01 |
|
|
